WO2010037130A3 - Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore - Google Patents
Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore Download PDFInfo
- Publication number
- WO2010037130A3 WO2010037130A3 PCT/US2009/058869 US2009058869W WO2010037130A3 WO 2010037130 A3 WO2010037130 A3 WO 2010037130A3 US 2009058869 W US2009058869 W US 2009058869W WO 2010037130 A3 WO2010037130 A3 WO 2010037130A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- compositions
- adipocyte cells
- reprogrammed adipocyte
- generating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
The invention provides therapeutic compositions comprising reprogrammed adipocyte cells for use as disease models, therapeutic compositions comprising reprogrammed adipocyte cells for the treatment of conditions characterized by a reduction in cell number or tissue mass, and methods of generating such cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/245,716 US20120219530A1 (en) | 1999-04-15 | 2011-09-26 | Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10094608P | 2008-09-29 | 2008-09-29 | |
US61/100,946 | 2008-09-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13121401 A-371-Of-International | 2009-09-29 | ||
US13/245,716 Continuation US20120219530A1 (en) | 1999-04-15 | 2011-09-26 | Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010037130A2 WO2010037130A2 (en) | 2010-04-01 |
WO2010037130A3 true WO2010037130A3 (en) | 2010-05-27 |
Family
ID=42060441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/058869 WO2010037130A2 (en) | 1999-04-15 | 2009-09-29 | Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010037130A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013082106A1 (en) * | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
US10253325B2 (en) | 2012-12-19 | 2019-04-09 | Boston Medical Center Corporation | Methods for elevating fat/oil content in plants |
FR3024462A1 (en) * | 2014-07-29 | 2016-02-05 | Univ Pierre Et Marie Curie Paris 6 | METHOD FOR IN VITRO PRODUCTION OF ADIPOCYTE PROGENITORS AND ADIPOCYTES |
WO2024084082A1 (en) * | 2022-10-21 | 2024-04-25 | Meatable B.V. | Adipocyte maturation |
-
2009
- 2009-09-29 WO PCT/US2009/058869 patent/WO2010037130A2/en active Application Filing
Non-Patent Citations (7)
Title |
---|
ANGHEL ET AL.: "Fat poetry: a kingdom for PPAR gamma.", CELL RES., vol. 17, no. 6, 2007, pages 486 - 511 * |
HEGELE.: "Lessons from human mutations in PPARgamma.", INT J OBES (LOND), vol. 29, no. SUP.1, 2005, pages S31 - S35 * |
JANDEROVA ET AL.: "Human mesenchymal stem cells as an in vitro model for human adipogenesis.", OBES RES., vol. 11, no. 1, 2003, pages 65 - 74 * |
LOWELL.: "PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function.", CELL, vol. 99, no. 3, 1999, pages 239 - 242 * |
SANDHU ET AL.: "LDL-cholesterol concentrations: a genome-wide association study.", LANCET, vol. 371, no. 9611, 9 February 2008 (2008-02-09), pages 483 - 491 * |
SHOCKLEY ET AL.: "PPARgamma2 Regulates aMolecular Signature of Marrow Mesenchymal Stem Cells.", PPAR RESEARCH., vol. 2007, pages 13, Retrieved from the Internet <URL:http://downloads.hindawi.com/journals/ppar/2007/081219.pdf> [retrieved on 20100327] * |
YUN ET AL.: "Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stral3: a mechanism for regulation of adipogenesis by hypoxia.", DEV CELL, vol. 2, no. 3, 2002, pages 331 - 341 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010037130A2 (en) | 2010-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL260117A (en) | Treatment of diseases, disorders or conditions of the lung using placental cells | |
IL233634A0 (en) | Methods, compositions, and kits for the treatment of medical conditions | |
EP2260109A4 (en) | Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders | |
WO2010017562A3 (en) | Induced pluripotent stem cells | |
BRPI0912292A2 (en) | compositions and methods for the use of cells in the treatment of cardiac tissue. | |
WO2010111409A3 (en) | Pluripotent stem cells | |
EP2212440A4 (en) | Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas | |
WO2009009620A3 (en) | Acellular tissue matrix compositions for tissue repair | |
MX2012011543A (en) | Treatment of sarcoidosis using placental stem cells. | |
IL198663A0 (en) | Tissue treatment methods | |
PL3135672T3 (en) | Compositions and methods for treating alcohol use disorders, pain and other diseases | |
WO2009022133A3 (en) | Scaffolds | |
WO2009114703A3 (en) | Combination therapy for the treatment of cancer | |
WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
WO2012018643A3 (en) | Compositions for proliferation of cells and related methods | |
ZA201000278B (en) | Human umbilical tissue-derived cell compositions for the treatment of incontinence | |
WO2010014595A3 (en) | Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders | |
WO2012048170A3 (en) | Humanized animals via tissue engineering and uses therefor | |
EP2039757A4 (en) | Method of cultivating cell or tissue | |
ZA201007005B (en) | Methods of diagnosing, preventing and treating bone mass diseases | |
EP1948246A4 (en) | Stem cell factor therapy for tissue injury | |
WO2010037130A3 (en) | Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore | |
WO2007025229A3 (en) | Compositions and their uses directed to hsp27 | |
EP2502989A4 (en) | Implant composition for the regeneration of neural tissue, process of preparation and uses thereof | |
WO2011041701A3 (en) | Inplantable contrast agents and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09817057 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09817057 Country of ref document: EP Kind code of ref document: A2 |